3rd IMPACCT Real World Evidence Summit Europe

Memo

As regulators and payers increasingly elevate the importance of RWE in submission and reimbursement requirements, the upcoming EHDS regulation marks a landmark move towards data sharing, and increasingly robust AI transforms big data analysis, it has never been more critical to harness RWE to uncover unmet needs, demonstrate treatment value beyond the clinical trial setting, and influence decision-making across regulators, payers, providers, and patients. The 3rd IMPACCT Real World Evidence Summit Europe is the only industry meeting dedicated to uniting experts in RWE, Evidence Generation, and Medical Affairs to consolidate, innovate and apply RWE across the drug development lifecycle, from external control arms to reimbursement. With a tight focus on leveraging AI for big data analysis, accessing standardised and high-quality datasets, and creating a robust integrated evidence strategy, join 60+ industry pioneers from AstraZeneca, Pfizer, Novartis, Boehringer Ingelheim and more to collaboratively establish best practice and bridge the evidence gap between clinical research and practice. URLs:Tickets: https://go.evvnt.com/3369380-2?pid=5569Brochure: https://go.evvnt.com/3369380-3?pid=5569 Date and Time: Tuesday, 24 February 2026 at 08:00 - Thursday, 26 February 2026 at 17:00 Venue details: Radisson Blu Hotel, Amsterdam City Center, 17 Rusland, Amsterdam, Noord-Holland, 1012 CK, Netherlands Category: Conferences | Science, Health and Medicine | Pharmaceuticals Prices:Drug Developer - Conference + Workshop Day: EUR 2897.00,Academic - Conference + Workshop Day: EUR 2397.00,Service Provider - Conference + Workshop Day: EUR 4597.00,Drug Developer - Conference Only: EUR 2199.00,Academic - Conference Only: EUR 1899.00,Service Provider - Conference Only: EUR 3599.00 Speakers: Alessandra Oortwijn, Global Head Evidence Generation, Alfasigma Spa, Ronald Vollebregt, Real World Data and Healthcare Technology Manager, Amgen Inc., Judith Nelissen, Vice President, Head of Global Value Evidence, Astellas Pharma Europe, Josie Wolfram, Senior Director, Real World Data Science, Astellas Pharma Europe, Katoo Muylle, Real World Evidence Manager, AstraZeneca, Suzanne St. Rose, Global Real-World Evidence Head in Eye Health and Emerging Areas, Boehringer Ingelheim, Carissa Dukes, Director, Global Epidemiology and Real-World Evidence, Boehringer Ingelheim, Lill-Brith Wium Von Arx, RWE Northern Europe Hub Lead, Senior Director, Eli Lilly and Co., Karin Luttropp, Senior Advisor Real World Evidence, Eli Lilly and Co., Debarshi Dey, Vice President and Head of Biometrics and Data Science, Galapagos, Zeki Kocaata, Senior Director, Global Real World Evidence and Health Outcomes Lead Vaccines, GlaxoSmithKline, Sandy Ruiz, Senior Director, Market Access, Pricing, Health Economics and Outcomes Research, Immunome, Inc., Kristine Harrsen, Real World Evidence Senior Specialist, Lundbeck, Swarna Khare, Director, Global Integrated Evidence Planning, Novartis, Renate Handrock, Head, Integrated Evidence and Innovation, Novartis, Michael Wallington, Director, Haematology Real World Data Science and Epidemiology, Pfizer, Antonella Chiucchiuini, Director, Fair Market Value Lead, Global Medical Evidence, Takeda Pharmaceutical, Melpomeni Styliadou, Vice President Global Program Leader, Health Data Partnerships, Takeda Pharmaceuticals, Steven Lister, EU Evidence Generation Strategy Lead, Rare Diseases, UCB, Lorenzo Mantovani, Director and Professor, Hygiene and Public Health, University of Milano-Bicocca